Cargando…

Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy

Pluronics are amphiphilic triblock copolymers composed of two hydrophilic poly (ethylene oxide) (PEO) chains linked via a central hydrophobic polypropylene oxide (PPO). Owing to their low molecular weight polymer and greater number of PEO segments, Pluronics induce micelle formation and gelation at...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaliq, Nisar Ul, Lee, Juyeon, Kim, Sangwoo, Sung, Daekyung, Kim, Hyungjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458801/
https://www.ncbi.nlm.nih.gov/pubmed/37631316
http://dx.doi.org/10.3390/pharmaceutics15082102
_version_ 1785097253154717696
author Khaliq, Nisar Ul
Lee, Juyeon
Kim, Sangwoo
Sung, Daekyung
Kim, Hyungjun
author_facet Khaliq, Nisar Ul
Lee, Juyeon
Kim, Sangwoo
Sung, Daekyung
Kim, Hyungjun
author_sort Khaliq, Nisar Ul
collection PubMed
description Pluronics are amphiphilic triblock copolymers composed of two hydrophilic poly (ethylene oxide) (PEO) chains linked via a central hydrophobic polypropylene oxide (PPO). Owing to their low molecular weight polymer and greater number of PEO segments, Pluronics induce micelle formation and gelation at critical micelle concentrations and temperatures. Pluronics F-68 and F-127 are the only United States (U.S.) FDA-approved classes of Pluronics and have been extensively used as materials for living bodies. Owing to the fascinating characteristics of Pluronics, many studies have suggested their role in biomedical applications, such as drug delivery systems, tissue regeneration scaffolders, and biosurfactants. As a result, various studies have been performed using Pluronics as a tool in nanomedicine and targeted delivery systems. This review sought to describe the delivery of therapeutic cargos using Pluronic F-68 and F-127-based cancer nanomedicines and their composites for combination therapy.
format Online
Article
Text
id pubmed-10458801
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104588012023-08-27 Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy Khaliq, Nisar Ul Lee, Juyeon Kim, Sangwoo Sung, Daekyung Kim, Hyungjun Pharmaceutics Review Pluronics are amphiphilic triblock copolymers composed of two hydrophilic poly (ethylene oxide) (PEO) chains linked via a central hydrophobic polypropylene oxide (PPO). Owing to their low molecular weight polymer and greater number of PEO segments, Pluronics induce micelle formation and gelation at critical micelle concentrations and temperatures. Pluronics F-68 and F-127 are the only United States (U.S.) FDA-approved classes of Pluronics and have been extensively used as materials for living bodies. Owing to the fascinating characteristics of Pluronics, many studies have suggested their role in biomedical applications, such as drug delivery systems, tissue regeneration scaffolders, and biosurfactants. As a result, various studies have been performed using Pluronics as a tool in nanomedicine and targeted delivery systems. This review sought to describe the delivery of therapeutic cargos using Pluronic F-68 and F-127-based cancer nanomedicines and their composites for combination therapy. MDPI 2023-08-09 /pmc/articles/PMC10458801/ /pubmed/37631316 http://dx.doi.org/10.3390/pharmaceutics15082102 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Khaliq, Nisar Ul
Lee, Juyeon
Kim, Sangwoo
Sung, Daekyung
Kim, Hyungjun
Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
title Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
title_full Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
title_fullStr Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
title_full_unstemmed Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
title_short Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
title_sort pluronic f-68 and f-127 based nanomedicines for advancing combination cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458801/
https://www.ncbi.nlm.nih.gov/pubmed/37631316
http://dx.doi.org/10.3390/pharmaceutics15082102
work_keys_str_mv AT khaliqnisarul pluronicf68andf127basednanomedicinesforadvancingcombinationcancertherapy
AT leejuyeon pluronicf68andf127basednanomedicinesforadvancingcombinationcancertherapy
AT kimsangwoo pluronicf68andf127basednanomedicinesforadvancingcombinationcancertherapy
AT sungdaekyung pluronicf68andf127basednanomedicinesforadvancingcombinationcancertherapy
AT kimhyungjun pluronicf68andf127basednanomedicinesforadvancingcombinationcancertherapy